- Biotech company Immutep (IMM) has released results from its breast cancer clinical trial
- The trial treated 227 breast cancer patients with Immutep’s efti treatment and a chemotherapy drug called paclitaxel (also known as Taxol)
- During the treatment, doctors aimed to boost the patients’ immune response to help fight tumours
- Results show progression-free survival was in favour of efti over the placebo at the six-month treatment mark
- Immutep said the combination of efti and paclitaxel chemotherapy was safe for patients and was well-tolerated
- The company is expecting to receive the overall survival data in late 2020
- Immutep will go over the results in more detail at its upcoming conference on Thursday
- Immutep is down 51.7 per cent on the market this morning, trading at 14.5¢ apiece
Biotech company, Immutep (IMM) has reported data from its breast cancer clinical trial.
The company recently completed its Phase IIb AIPAC clinical trial, with an aim to beat cancer.
The clinical trial
AIPAC is a study evaluating its lead treatment eftilagimod alpha (or efti for short). The company treated 227 metastatic breast cancer (MBC) with efti and paclitaxel (Taxol- chemotherapy medication) to boost the T-cell immune response against tumours.
Results showed progression-free survival (PFS) was in favour of efti over the placebo at the 6-month mark.
PFS is the length of time during and after the treatment of cancer that the patient lives with the disease, but it does not get worse.
Immutep said 63 per cent of the patients who received paclitaxel and efti were progression-free at the end of six months. This result is higher than the 54 per cent of patients who didn’t have efti.
The secondary endpoint showed the overall response rate (ORR) increased to 48.3 per cent in the efti group, up from 38.4 per cent.
The study found that patients with low white blood cell counts had a positive hazard ratio (HR) of 0.61. The median (middle number) for the efti group was over 7 months (7.16); compared to the placebo, which was just over 6 months (6.7).
The company said the combination of efti and paclitaxel chemotherapy was overall safe and well-tolerated.
Immutep CEO Marc Voigt is pleased with these results and to see a clinical benefit got the patients receiving efti.
“This is just one of the four advanced solid tumour indications targeted in our efti clinical development program,” he said.
“We are pleased to see an efficacy trend and will carefully assess the data for further development of efti given our positive data in patient subgroups,” he added.
These results, together with the overall survival and the immuno-monitoring data, expected to be reported later this year, could allow Immutep to plan for phase III of efti in the metastatic breast cancer (cancer that has spread beyond the breast).
Immutep is expecting to receive the overall survival data in late 2020.
The company said it will go over the results in more detail at its upcoming conference on Thursday.
“I am pleased to see this innovative chemo-immunotherapy approach in AIPAC is well tolerated by patients, while showing a numerically (non-significant) higher progression-free survival rate compared to chemotherapy alone,” AIPAC Principal Investigator, Hans Wildiers said.
“Hormone receptor-positive breast tumours represent the majority of metastatic breast cancer patients and any active well-tolerated adjunct to the weekly paclitaxel standard of care regimen, is desirable,” he added.
Immutep is down 51.7 per cent on the market this morning, trading at 14.5¢ apiece at 11:48 am AEDT.